Tudor Investment Corp ET AL Invests $808,000 in OraSure Technologies, Inc. $OSUR

Tudor Investment Corp ET AL bought a new position in OraSure Technologies, Inc. (NASDAQ:OSUR) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 251,867 shares of the medical instruments supplier’s stock, valued at approximately $808,000. Tudor Investment Corp ET AL owned about 0.35% of OraSure Technologies at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in OSUR. Prudential Financial Inc. bought a new stake in OraSure Technologies during the 2nd quarter worth approximately $31,000. L2 Asset Management LLC bought a new position in shares of OraSure Technologies in the second quarter valued at approximately $39,000. Coldstream Capital Management Inc. lifted its holdings in shares of OraSure Technologies by 128.2% in the second quarter. Coldstream Capital Management Inc. now owns 13,308 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 7,477 shares in the last quarter. Amundi purchased a new position in shares of OraSure Technologies during the first quarter valued at approximately $47,000. Finally, BNP Paribas Financial Markets grew its holdings in OraSure Technologies by 102.2% during the third quarter. BNP Paribas Financial Markets now owns 15,275 shares of the medical instruments supplier’s stock worth $49,000 after buying an additional 7,720 shares in the last quarter. Institutional investors own 93.50% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d)” rating on shares of OraSure Technologies in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $3.00.

OraSure Technologies Stock Down 2.7%

OraSure Technologies stock opened at $2.92 on Tuesday. OraSure Technologies, Inc. has a 52 week low of $2.08 and a 52 week high of $3.82. The company’s 50 day moving average price is $2.90 and its two-hundred day moving average price is $2.78. The stock has a market cap of $201.86 million, a P/E ratio of -3.14 and a beta of 0.88.

OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Wednesday, February 25th. The medical instruments supplier reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.02). The business had revenue of $26.76 million during the quarter, compared to the consensus estimate of $26.44 million. OraSure Technologies had a negative net margin of 59.76% and a negative return on equity of 16.45%. On average, equities analysts anticipate that OraSure Technologies, Inc. will post -0.08 EPS for the current year.

Insiders Place Their Bets

In other OraSure Technologies news, CFO Kenneth J. Mcgrath bought 32,300 shares of the firm’s stock in a transaction dated Friday, March 20th. The stock was purchased at an average cost of $2.93 per share, with a total value of $94,639.00. Following the transaction, the chief financial officer directly owned 589,562 shares in the company, valued at $1,727,416.66. This trade represents a 5.80% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Manner Carrie Eglinton bought 32,300 shares of the firm’s stock in a transaction dated Friday, March 20th. The shares were acquired at an average cost of $2.93 per share, with a total value of $94,639.00. Following the completion of the transaction, the chief executive officer owned 2,190,874 shares in the company, valued at approximately $6,419,260.82. The trade was a 1.50% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired a total of 108,643 shares of company stock valued at $321,407 in the last 90 days. Corporate insiders own 3.90% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.